Premium
Neomycin and plasma lipoproteins in type II hyperlipoproteinemia
Author(s) -
Hoeg Jeffrey M,
Schaefer Ernst J,
Romano Carol A,
Bou Ernestina,
Pikus Anita M,
Zech Loren A,
Bailey Kent R,
Gregg Richard E,
Wilson Peter W F,
Sprecher Dennis L,
Grimes Alison M,
Sebring Nancy G,
Ayres Elaine J,
Jahn Claus E,
Brewer H B
Publication year - 1984
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1984.219
Subject(s) - neomycin , medicine , nephrotoxicity , chemistry , aminoglycoside , endocrinology , lipoprotein , cholesterol , crossover study , very low density lipoprotein , antibiotics , placebo , pharmacology , kidney , biochemistry , alternative medicine , pathology
Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9‐mo, double‐blind, randomized, crossover, placebo‐controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safety, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%) decline in plasma cholesterol concentration was observed with neomycin. Most of this effect resulted from a 41 mg% (16%) decrease in low‐density lipoprotein cholesterol concentration. No significant or consistent effect on the concentration of high‐density lipoprotein cholesterol was observed. Monthly audiologic and renal evaluation disclosed no oto‐ or nephrotoxicity. Neomycin treatment in patients with type II hyperlipoproteinemia is an inexpensive and effective means of lowering the concentration of low‐density lipoproteins and is free of significant side effects over a 3‐mo period. Clinical Pharmacology and Therapeutics (1984) 36, 555–565; doi: 10.1038/clpt.1984.219